These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 27712648)

  • 1. Impact of Lipoprotein(a) on Long-term Outcomes in Patients With Diabetes Mellitus Who Underwent Percutaneous Coronary Intervention.
    Konishi H; Miyauchi K; Shitara J; Endo H; Wada H; Doi S; Naito R; Tsuboi S; Ogita M; Dohi T; Kasai T; Okazaki S; Isoda K; Suwa S; Daida H
    Am J Cardiol; 2016 Dec; 118(12):1781-1785. PubMed ID: 27712648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention.
    Konishi H; Miyauchi K; Kasai T; Tsuboi S; Ogita M; Naito R; Sai E; Fukushima Y; Katoh Y; Okai I; Tamura H; Okazaki S; Daida H
    Am J Cardiol; 2015 Jan; 115(2):157-60. PubMed ID: 25476560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention.
    Konishi H; Miyauchi K; Tsuboi S; Ogita M; Naito R; Dohi T; Kasai T; Tamura H; Okazaki S; Isoda K; Daida H
    Int J Cardiol; 2016 Feb; 205():50-53. PubMed ID: 26710333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of lipoprotein (a) on long-term clinical outcomes in diabetic patients on statin treatment after percutaneous coronary intervention.
    Takahashi N; Dohi T; Funamizu T; Endo H; Wada H; Doi S; Kato Y; Ogita M; Okai I; Iwata H; Okazaki S; Isoda K; Miyauchi K; Shimada K
    J Cardiol; 2020 Jul; 76(1):25-29. PubMed ID: 32089480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Lipoprotein (a) on Long-Term Outcomes in Patients with Coronary Artery Disease Treated with Statin After a First Percutaneous Coronary Intervention.
    Suwa S; Ogita M; Miyauchi K; Sonoda T; Konishi H; Tsuboi S; Wada H; Naito R; Dohi T; Kasai T; Okazaki S; Isoda K; Daida H
    J Atheroscler Thromb; 2017 Nov; 24(11):1125-1131. PubMed ID: 28321012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Plasma Lipoprotein(a) With Long-Term Adverse Events in Patients With Chronic Kidney Disease Who Underwent Percutaneous Coronary Intervention.
    Xu N; Tang XF; Yao Y; Zhao XY; Chen J; Gao Z; Qiao SB; Yang YJ; Gao RL; Xu B; Yuan JQ
    Am J Cardiol; 2018 Dec; 122(12):2043-2048. PubMed ID: 30477725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of gender difference on long-term outcomes of percutaneous coronary intervention for coronary artery disease in patients under statin treatment.
    Wada H; Ogita M; Miyauchi K; Shitara J; Endo H; Doi S; Naito R; Konishi H; Tsuboi S; Dohi T; Kasai T; Tamura H; Okazaki S; Isoda K; Suwa S; Daida H
    Heart Vessels; 2017 Jan; 32(1):16-21. PubMed ID: 27107767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic kidney disease and diabetes associated with long-term outcomes in patients receiving percutaneous coronary intervention.
    Lin MJ; Lee J; Chen CY; Huang CC; Wu HP
    BMC Cardiovasc Disord; 2017 Sep; 17(1):242. PubMed ID: 28893175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Combined C-Reactive Protein and High-Density Lipoprotein Cholesterol Levels on Long-Term Outcomes in Patients With Coronary Artery Disease After a First Percutaneous Coronary Intervention.
    Ogita M; Miyauchi K; Tsuboi S; Shitara J; Endo H; Wada H; Doi S; Naito R; Konishi H; Dohi T; Kasai T; Tamura H; Okazaki S; Suwa S; Daida H
    Am J Cardiol; 2015 Oct; 116(7):999-1002. PubMed ID: 26243577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LDL-C and hs-CRP Jointly Modify the Effect of Lp(a) on 5-Year Death in Patients With Percutaneous Coronary Intervention.
    Li J; Yan K; Zhu P; Tang X; Yang Y; Gao R; Yuan J; Zhao X
    Clin Cardiol; 2024 Oct; 47(10):e70025. PubMed ID: 39428896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between lipoprotein(a) and revascularization after percutaneous coronary intervention in type 2 diabetes mellitus patients with acute coronary syndrome.
    Hao Y; Yang Y; Wang Y; Li J
    Curr Med Res Opin; 2022 Oct; 38(10):1663-1672. PubMed ID: 35575139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients.
    Kwon SW; Lee BK; Hong BK; Kim JY; Choi EY; Sung JM; Rhee JH; Park YM; Ma DW; Chung H; Mun HS; Lee SJ; Park JK; Min PK; Yoon YW; Rim SJ; Kwon HM
    Int J Cardiol; 2013 Sep; 167(5):1990-4. PubMed ID: 22633779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing mortality between coronary artery bypass grafting and percutaneous coronary intervention with drug-eluting stents in elderly with diabetes and multivessel coronary disease.
    Naito R; Miyauchi K; Konishi H; Tsuboi S; Ogita M; Dohi T; Kajimoto K; Kasai T; Tamura H; Okazaki S; Isoda K; Yamamoto T; Amano A; Daida H
    Heart Vessels; 2016 Sep; 31(9):1424-9. PubMed ID: 26412228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of high-sensitivity C-reactive protein during follow-up on long-term adverse clinical outcomes in patients with coronary artery disease treated with percutaneous coronary intervention.
    Shitara J; Ogita M; Wada H; Tsuboi S; Endo H; Doi S; Konishi H; Naito R; Dohi T; Kasai T; Okazaki S; Isoda K; Suwa S; Miyauchi K; Daida H
    J Cardiol; 2019 Jan; 73(1):45-50. PubMed ID: 30001869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of lipoprotein(a) with long-term mortality following coronary angiography or percutaneous coronary intervention.
    Feng Z; Li HL; Bei WJ; Guo XS; Wang K; Yi SX; Luo DM; Li XD; Chen SQ; Ran P; Chen PY; Islam SMS; Chen JY; Liu Y; Zhou YL
    Clin Cardiol; 2017 Sep; 40(9):674-678. PubMed ID: 28444976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein(a) and Cardiovascular Outcomes in Patients With Coronary Artery Disease and Prediabetes or Diabetes.
    Jin JL; Cao YX; Zhang HW; Sun D; Hua Q; Li YF; Guo YL; Wu NQ; Zhu CG; Gao Y; Dong QT; Liu HH; Dong Q; Li JJ
    Diabetes Care; 2019 Jul; 42(7):1312-1318. PubMed ID: 31076417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of serum albumin levels on long-term outcomes in patients undergoing percutaneous coronary intervention.
    Wada H; Dohi T; Miyauchi K; Shitara J; Endo H; Doi S; Naito R; Konishi H; Tsuboi S; Ogita M; Kasai T; Okazaki S; Isoda K; Suwa S; Daida H
    Heart Vessels; 2017 Sep; 32(9):1085-1092. PubMed ID: 28429111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of stage of chronic kidney disease on the outcomes of diabetics with acute myocardial infarction treated with percutaneous coronary intervention.
    Vichova T; Knot J; Ulman J; Maly M; Motovska Z
    Int Urol Nephrol; 2016 Jul; 48(7):1137-43. PubMed ID: 26995007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression and prognostic value of ischemia modified albumin (IMA), red blood cell distribution width (RDW), and lipoprotein (LP) in patients with diabetes mellitus complicated with coronary heart disease.
    Xiang L; Zhang M; Wu H; Xie D
    Ann Palliat Med; 2021 Apr; 10(4):4463-4471. PubMed ID: 33894715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of lipoprotein(a) on long-term outcomes after percutaneous coronary intervention in patients with reduced low-density lipoprotein cholesterol.
    Liu Y; Zeng Z; Yu X; Li T; Yao Y; Chen R; Zheng J
    Rev Cardiovasc Med; 2020 Mar; 21(1):147-153. PubMed ID: 32259914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.